Effect of pravastatin on blood pressure in people with cardiovascular disease

Journal of Human Hypertension

Volumn 20, Issue 8, 2006, Pages 560-565

  Tonelli, M ^a,b   Sacks, F ^c   Pfeffer, M ^d   Lopez Jimenez, F ^e   Jhangri, G S ^b   Curhan, G ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Department of Public Health Sciences ^*  (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; PLACEBO; PRAVASTATIN; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFOUNDING VARIABLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; POST HOC ANALYSIS; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; RISK FACTORS;

EID: 33746257177     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002036     Document Type: Article

References (32)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615.
3. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005.
4. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110(12): 1557.
5. Halcox JP, Deanfield JE. Beyond the laboratory: Clinical implications for statin pleiotropy. Circulation 2004; 109(21, Suppl 1): II42-II48.
6. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23(5): 729-736.
7. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286(1): 64.
8. Laufs U, La FV, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97(12): 1129-1135.
9. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154(1): 87-96.
10. Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000; 102(8): 846-851.
11. Wierzbicki AS. Lipid lowering: Another method of reducing blood pressure? J Hum Hypertens 2002; 16(11): 753-760.
12. Goode GK, Miller JP, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345(8948): 362-364.
13. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: Role of eNOS and oxidant stress. Hypertension 2004; 44(2): 186-190.
14. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003; 42(6): 1091-1097.
15. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003; 63(1): 360.
16. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148(2): 285-292.
17. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39(6): 1020-1025.
18. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005; 19(2): 103-109.
19. NKF-K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis 2002; 39(2 Suppl 1): S76.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289(19): 2560.
21. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95(5): 1126.
22. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100(21): 2131.
23. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290(22): 2945-2951.
24. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110(24): 3687-3692.
25. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83(10): 1497.
26. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli ED, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35(4): 549-555.
27. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30(11): 980-987.
28. Foss OP, Graff-Iversen S, Istad H, Soyland E, Tjeldflaat L, Graving B. Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention. Scand J Prim Health Care 1999; 17(2): 122-127.
29. O'Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG et al. Short term effects, of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Pressure 1994; 3(6): 404-406.
30. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
31. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001; 19(6): 1139-1147.
32. Poulter NR, Sever PS, Dahlof B, Wedel H. Do statins lower blood pressure? Evidence from the ASCOT-LLA trial. J Hum Hypertens 2004; 18(Suppl 4): S4.